|Bid||49.66 x 400|
|Ask||49.67 x 1100|
|Day's Range||48.96 - 50.02|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||12.35|
|Dividend & Yield||1.64 (3.40%)|
|1y Target Est||N/A|
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.
Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.